Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment

MLA

Duangchit Panomvana, et al. “Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai Breast Cancer Patients Undergoing Tamoxifen Treatment.” Breast Cancer: Targets and Therapy, vol. 8, Aug. 2016, pp. 149–55. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........eb3ff98b411163cdf57c43b0f0f3518f&authtype=sso&custid=ns315887.

APA

Duangchit Panomvana, Nutthada Areepium, Virote Sriuranpong, & Wanaporn Charoenchokthavee. (2016). Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer: Targets and Therapy, 8, 149–155.

Chicago

Duangchit Panomvana, Nutthada Areepium, Virote Sriuranpong, and Wanaporn Charoenchokthavee. 2016. “Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai Breast Cancer Patients Undergoing Tamoxifen Treatment.” Breast Cancer: Targets and Therapy 8 (August): 149–55. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........eb3ff98b411163cdf57c43b0f0f3518f&authtype=sso&custid=ns315887.